-
Mashup Score: 0
The European Union’s antitrust regulator says the acquisition of Grail would stifle innovation and reduce choice in the blood-test market, putting a $7.1 billion merger into jeopardy after a U.S. judge allowed it to proceed.
Source: WSJCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Blood test for cancer available, but is it ready for prime time? - 2 year(s) ago
“The devil is in the details to ensure the test can accurately detect very early cancers and there is a pathway for subsequent workup.”
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#BloodTest for cancer available, but is it ready for #PrimeTime?👇 https://t.co/25PUlv5J9N @MDedgeHemOnc #GRAIL https://t.co/3mUdjVhRGo
-
-
Mashup Score: 2Opinion | Regulatory Hurdles Block a Cancer Miracle - 3 year(s) ago
Illumina’s CEO Francis deSouza explains the Grail diagnostic test and the FTC action that risks slowing it down.
Source: WSJCategories: Healthcare Professionals, Latest HeadlinesTweet-
US Regulatory Hurdles Block a Cancer Miracle: @illumina ’s CEO @fdesouza explains the #Grail diagnostic test and the @FTC action that risks slowing it down. https://t.co/uCXINCNEka via @AllysiaFinley @susan_bewley @MichaelBaum11 @paulpharoah
-
-
Mashup Score: 1Grail Will Begin Selling Its Multi-Cancer Blood Test - 3 year(s) ago
The private cancer testing firm Grail said early Friday that it had begun selling its multi-cancer blood test in the U.S.
Source: www.barrons.comCategories: Cardiologists, Latest HeadlinesTweet-
Grail Will Begin Selling Its Multi-Cancer Blood Test. It Could Be the Start of a Huge Market. #grail #Cancer #CancerResearch #cancer @GrailBio https://t.co/Ciy6reKGFf via @Barronsonline
-
'#Illumina’s #Grail acquisition would stifle innovation & choice in early cancer-detection blood test mkt' https://t.co/nLQc45K59a via @WSJ | 'The bloc’s move isn’t unprecedented [US-EU] divergence, but is unusual, esp bcs it involves a co w/o EU revenues' #antitrust #HarlowOnHC